DK3802517T3 - Alkoxy-substituerede pyridinylderivater som lpa1-receptorantagonister og deres anvendelse i behandlingen af fibrose - Google Patents

Alkoxy-substituerede pyridinylderivater som lpa1-receptorantagonister og deres anvendelse i behandlingen af fibrose Download PDF

Info

Publication number
DK3802517T3
DK3802517T3 DK19731163.2T DK19731163T DK3802517T3 DK 3802517 T3 DK3802517 T3 DK 3802517T3 DK 19731163 T DK19731163 T DK 19731163T DK 3802517 T3 DK3802517 T3 DK 3802517T3
Authority
DK
Denmark
Prior art keywords
fibrosis
treatment
receptor antagonists
alkoxy substituted
substituted pyridinyl
Prior art date
Application number
DK19731163.2T
Other languages
Danish (da)
English (en)
Inventor
Martin Bolli
Christine Brotschi
Cyrille Lescop
Jodi T Williams
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Application granted granted Critical
Publication of DK3802517T3 publication Critical patent/DK3802517T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DK19731163.2T 2018-06-07 2019-06-05 Alkoxy-substituerede pyridinylderivater som lpa1-receptorantagonister og deres anvendelse i behandlingen af fibrose DK3802517T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2018065016 2018-06-07
PCT/EP2019/064690 WO2019234115A1 (en) 2018-06-07 2019-06-05 Alkoxy-substituted pyridinyl derivatives as lpa1 receptor antagonists and their use in the treatment of fibrosis

Publications (1)

Publication Number Publication Date
DK3802517T3 true DK3802517T3 (da) 2023-03-13

Family

ID=66912779

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19731163.2T DK3802517T3 (da) 2018-06-07 2019-06-05 Alkoxy-substituerede pyridinylderivater som lpa1-receptorantagonister og deres anvendelse i behandlingen af fibrose

Country Status (22)

Country Link
US (1) US12344597B2 (enExample)
EP (1) EP3802517B1 (enExample)
JP (1) JP7386183B2 (enExample)
KR (1) KR102826034B1 (enExample)
CN (1) CN112236424B (enExample)
AU (1) AU2019282274A1 (enExample)
BR (1) BR112020024879A2 (enExample)
CA (1) CA3102683A1 (enExample)
DK (1) DK3802517T3 (enExample)
EA (1) EA202092955A1 (enExample)
ES (1) ES2940695T3 (enExample)
FI (1) FI3802517T3 (enExample)
HR (1) HRP20230243T1 (enExample)
HU (1) HUE061559T2 (enExample)
LT (1) LT3802517T (enExample)
MX (1) MX2020013291A (enExample)
PL (1) PL3802517T3 (enExample)
PT (1) PT3802517T (enExample)
RS (1) RS63990B1 (enExample)
SI (1) SI3802517T1 (enExample)
TW (1) TW202016090A (enExample)
WO (1) WO2019234115A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR119162A1 (es) * 2019-06-18 2021-12-01 Idorsia Pharmaceuticals Ltd Derivados de piridin-3-ilo
WO2021110805A1 (en) * 2019-12-04 2021-06-10 Idorsia Pharmaceuticals Ltd Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases
FI20225388A1 (en) * 2022-05-05 2023-11-06 Equinorm Ltd New heterocyclic compounds, preparation methods and their uses
WO2025169931A1 (ja) * 2024-02-05 2025-08-14 Ube株式会社 カルボキサミド化合物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL130088C (enExample) 1960-03-14
GB9420763D0 (en) 1994-10-14 1994-11-30 Glaxo Inc Acetamide derivatives
GB9919776D0 (en) 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
AU7961300A (en) 1999-10-29 2001-05-14 Yamanouchi Pharmaceutical Co., Ltd. Kainic acid neurocytotoxicity inhibitors
AU2001262185A1 (en) 2000-04-10 2001-10-23 Novartis Ag Substituted (hetero)aryl carboxamide derivatives as microsomal triglyceride transfer protein (mtp) and apolipoprotein b (apo b) secretion
EP1364659B1 (en) 2001-02-08 2009-11-11 Ono Pharmaceutical Co., Ltd. Remedies for urinary diseases comprising lpa receptor controlling agents
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
US7435824B2 (en) 2002-04-19 2008-10-14 Bristol-Myers Squibb Company Prodrugs of potassium channel inhibitors
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
CN102584813B (zh) 2003-05-14 2016-07-06 Ngc药物公司 化合物及其在调节淀粉样蛋白β中的用途
SG146624A1 (en) 2003-09-11 2008-10-30 Kemia Inc Cytokine inhibitors
WO2005037269A1 (ja) 2003-10-21 2005-04-28 Dainippon Sumitomo Pharma Co., Ltd. 新規ピペリジン誘導体
EP1687296A1 (en) 2003-11-18 2006-08-09 Warner-Lambert Company LLC Antibacterial aminoquinazolidinedione derivatives
WO2006091862A2 (en) 2005-02-24 2006-08-31 Kemia, Inc. Cytokine inhibitors and their use in therapy
TWI377198B (en) 2005-08-24 2012-11-21 Eisai R&D Man Co Ltd Novel pyridine derivatives and pyrimidine derivatives (3)
WO2007058990A2 (en) 2005-11-14 2007-05-24 Kemia, Inc. Therapy using cytokine inhibitors
EP2035005A4 (en) 2006-06-09 2011-07-06 Kemia Inc THERAPY BASED ON CYTOKINE INHIBITORS
JP5164510B2 (ja) 2006-10-06 2013-03-21 日本曹達株式会社 含窒素複素環化合物および有害生物防除剤
WO2008115281A2 (en) 2006-10-16 2008-09-25 Myriad Genetics, Inc. Compounds for treating viral infections
AU2008311971A1 (en) 2007-10-18 2009-04-23 Merck Sharp & Dohme Corp. Quinolizidinone M1 receptor positive allosteric modulators
EP2297153B1 (en) 2008-04-21 2015-05-27 Lexicon Pharmaceuticals, Inc. Limk2 inhibitors, compositions comprising them, and methods of their use
AU2009243756B2 (en) 2008-05-05 2013-06-27 Sanofi-Aventis Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals
BRPI0918971A2 (pt) 2008-08-26 2015-12-01 Boehringer Ingelheim Int tienopirimidinas para composições farmacêuticas
JP5708936B2 (ja) 2009-09-25 2015-04-30 アステラス製薬株式会社 置換アミド化合物
ES2682303T3 (es) 2010-08-05 2018-09-19 Zoetis Services Llc Derivados de isoxazolina como agentes antiparasitarios
TW201305178A (zh) 2010-10-29 2013-02-01 Glenmark Pharmaceuticals Sa 作為mPGES-1抑制物的三環化合物
CN107721940A (zh) 2010-12-07 2018-02-23 阿米拉制药公司 多环lpa1拮抗剂及其使用
EP2651930B1 (en) 2010-12-16 2015-10-28 Boehringer Ingelheim International GmbH Biarylamide inhibitors of leukotriene production
PT2683723T (pt) 2011-03-10 2016-08-05 Zoetis Services Llc Derivados espirocíclicos de isoxazolina como agentes antiparasitários
JP2015506349A (ja) 2011-12-21 2015-03-02 アルデリックス, インコーポレイテッド 非全身性tgr5アゴニスト
WO2014079805A1 (en) 2012-11-23 2014-05-30 Boehringer Ingelheim International Gmbh Pyrazole compounds for treating hairloss
TW201444820A (zh) * 2013-03-13 2014-12-01 Abbvie Inc 吡啶cdk9激酶抑制劑
AR108185A1 (es) 2016-04-06 2018-07-25 Abbvie Inc Amidas terciarias y método para su uso
AR119162A1 (es) 2019-06-18 2021-12-01 Idorsia Pharmaceuticals Ltd Derivados de piridin-3-ilo
WO2021110805A1 (en) 2019-12-04 2021-06-10 Idorsia Pharmaceuticals Ltd Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases

Also Published As

Publication number Publication date
KR102826034B1 (ko) 2025-06-27
KR20210018900A (ko) 2021-02-18
CN112236424A (zh) 2021-01-15
BR112020024879A2 (pt) 2021-03-09
CA3102683A1 (en) 2019-12-12
WO2019234115A1 (en) 2019-12-12
JP7386183B2 (ja) 2023-11-24
AU2019282274A1 (en) 2021-01-28
EA202092955A1 (ru) 2021-04-08
FI3802517T3 (fi) 2023-03-23
PL3802517T3 (pl) 2023-05-22
US12344597B2 (en) 2025-07-01
US20210246116A1 (en) 2021-08-12
TW202016090A (zh) 2020-05-01
CN112236424B (zh) 2024-03-15
LT3802517T (lt) 2023-03-10
EP3802517B1 (en) 2022-12-21
MX2020013291A (es) 2021-04-29
ES2940695T3 (es) 2023-05-10
RS63990B1 (sr) 2023-03-31
HRP20230243T1 (hr) 2023-04-14
JP2021527046A (ja) 2021-10-11
HUE061559T2 (hu) 2023-07-28
EP3802517A1 (en) 2021-04-14
PT3802517T (pt) 2023-03-20
SI3802517T1 (sl) 2023-04-28

Similar Documents

Publication Publication Date Title
DK3917616T3 (da) Heterocykliske forbindelser og anvendelse deraf
LT3806955T (lt) Glp-1 receptoriaus antagonistai ir jų panaudojimo būdai
DK3810591T3 (da) Pyridinyl- og pyrazinyl-(aza)indolsulfonamider
DK3526207T3 (da) Heterocykliske forbindelser med aktivitet som modulatorer af muscarine m1- og/eller m4-receptorer i behandling af cns-sygdomme og smerter
DK3621439T3 (da) 4-amino-6-(heterocykliske)picolinater og 6-amino-2-(heterocykliske)pyrimidin-4-carboxylater og deres anvendelse som herbicider
DK3325509T3 (da) Anti-tfr antistoffer og deres anvendelse i behandling af proliferative og inflammatoriske lidelser
IL278546A (en) Activin receptor type iia variants and methods of use thereof
IL292692A (en) Mrgprx2 antagonists and uses thereof
IL282588A (en) Heterocyclic kinase inhibitors and uses thereof
DK3215511T3 (da) Substituerede pyrazolo(1,5-a)pyrimidiner og deres anvendelse i behandlingen af medicinske lidelser
DK3658140T3 (da) Kombinationer af aprocitentan med yderligere aktive bestanddele til behandlingen af resistent hypertension
DK3786160T3 (da) Pyridinderivater og terapeutiske anvendelser deraf som trpc6-inhibitorer
DK3852748T3 (da) Farnesoid x-receptor-agonister og deres anvendelse
IL251818B (en) Crystalline forms of 5-chloro-n4-[2-(dimethylphosphoryl)phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]pyrimidine-2,4-diamine
DK3319963T3 (da) Substituerede 4-azaindoler og deres anvendelse som glun2b receptormodulatorer
IL285025A (en) History of heterocyclic carboxamides, their preparation and use
SI4076652T1 (sl) Farmacevtsko sprejemljiva sol atrazentana za uporabo v zdravljenju iga nefropatije
EP3868408A4 (en) ANTISYCHOTIC AND ITS USE
SI3262028T1 (sl) N-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamidne in N-(-4hidroksi-4-metil-cikloheksil)-4-(2-piridil)-benzensulfonamidne spojine in njihova terapevtska uporaba
EP3541378A4 (en) ALLOSTERIC ANTAGONISTS OF GPRC6A AND THEIR USE IN THE MITIGATION OF PROTEINOPATHIES
IL280520A (en) Compounds useful in paranoid X receptor modulation and methods of making and using them
EP3543239C0 (en) SELECTIVE INHIBITOR OF BRUTON'S TYROSINE KINASE AND ITS USE
DK3722291T3 (da) Indolinonforbindelser og deres anvendelse i behandlingen af fibrotiske sygdomme
EP3882247A4 (en) SIX-MEMBERED, SIX-MEMBERED, HETEROCYCLIC COMPOUND AND USES OF THEREOF AS A PROTEIN KINASE RECEPTOR INHIBITOR
EP3675860A4 (en) SUBSTITUTED PYRIMIDINS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC PROCEDURES THEREFORE